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Reply to Callen
To the Editor:
In our recent article in the Journal (Yang et al. 1997),
we showed that an interstitial deletion of 17p11.2 had
arisen after meiotic recombination in a carrier of an ap-
parently balanced paracentric inversion (PAI; with
breakpoints at 17p11.2 and 17p13.3). Considering all
the cytogenetic and molecular evidence, especially the
facts that (a) the breakpoints of the proband’s interstitial
deletion “flanked” the proximal breakpoint of the pa-
ternal PAI (the proximal Smith-Magenis syndrome
(SMS) markers were deleted in spite of not being in-
verted), (b) some markers involved in the PAI were not
deleted (the PMP22 locus), and (c) the position of the
recombination in paternal meiosis was mapped within
the immediate vicinity of the resulting deletion, we pro-
posed a model of unequal crossing-over at the base of
an inversion loop.
In response to our article, Callen has raised an inter-
esting point. He proposes an alternate explanation,
wherein pairing at meiosis, followed by recombination
between an insertion-bearing and the normal chromo-
some 17 homologue could result in the interstitial chro-
mosomal deletion observed in the proband. We agree
that a within-arm direct or inverted insertion is an im-
portant differential diagnosis in cases of suspected para-
centric inversions, given the significantly enhanced risk
of chromosomal imbalance associated with the former.
However, although within-arm insertions (direct or in-
verted) can result in deletion or duplication of the in-
serted sequence (Gardner and Sutherland 1996), they
cannot result in a concurrent deletion of noninserted
sequences (proximal SMS markers) and sparing of in-
serted sequences (PMP22 markers).
Taken together, the data seem to favor our hypothesis
of an unequal crossing-over at meiosis, as proposed in
our article. However, it should be noted that we have
yet to formally exclude Callen’s proposal—or even the
possibility that the deletion arose de novo as a result of
a slightly more proximal (unequal) recombination in
17p11.2.
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Anticipation in Familial Hodgkin Lymphoma
To the Editor:
Anticipation in childhood malignancy has been de-
scribed by several investigators (Horwitz et al. 1996;
Plon 1997). On the basis of 21 parent-child pairs with
acute myelogenous leukemia and 9 parent-child pairs
with chronic lymphocytic leukemia identified from the
literature, Horwitz et al. rejected the hypothesis that
there was no age-at-onset difference between the two
generations, in either data set. Several published data
sets were pooled to test whether there is a difference in
parent-child pairs affected with Hodgkin lymphoma
(HL). Because the occurrence of HL parent-child pairs
is a rare event, several published data sets were pooled
to test whether there is a difference, in cancer age at
onset, between parents and children who are affected
with HL. Thirty parent-child pairs with confirmed di-
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Table 1
Pooled Parent-Child Pairs with Hodgkin Lymphoma
Reference
Parent (Age
at Diagnosis
[years])
Child (Age at
Diagnosis
[years])
Devore and Doan (1957) Father (33) Son (27)
Mother (59) Son (28)
Father (60) Daughter (29)
Father (50) Daughter (23)
Razis et al. (1959) Mother (38) Son (20)
Mother (52) Son (14)
Father (40) Daughter (38)
Mother (52) Son (46)
Mother (40) Son (13)
Mother (47) Daughter (19)
Father (53) Daughter (16)
Vianna et al. (1974) Father (65) Son (43)
Mother (40) Son (21)
Father (43) Son (23)
Father (45) Daughter (18)
Father (50) Son (18)
Mother (41) Son (28)
Mother (41) Daughter (16)
Hors et al. (1980) Mother (47) Daughter (15)
Father (50) Son (18)
Father (44) Son (21)
Mother (46) Daughter (24)
Haim et al. (1982) Mother (26) Daughter (28)
Father (44) Daughter (19)
Hors and Dausset (1983) Father (39) Son (18)
Son (12)
Cimino et al. (1988) Father (67) Daughter (30)
Father (41) Daughter (9)
Father (34) Daughter (9)
Father (41) Son (9)
agnosis and well-documented age at diagnosis were in-
cluded in this study. Age at onset and data sources are
listed in table 1. In all pairs except one, HL children
reveal a younger age at onset. The mean age at onset is
46 years in parents and 22 years in children. This sig-
nificant difference between the age at diagnosis of par-
ents and that of children was detected by use of the
Mann-Whitney test ( , , ).N  30 U  40.5 P ! .0001
One may argue that the smaller number of parents of
relatively young age among the pairs reported in the 50s
may be due to reduced fitness, as a consequence of
poorer treatment. To address this issue, the analysis was
repeated after removal of these pairs. The age-at-onset
difference between the two generations remained sig-
nificant (Mann-Whitney; , , ),N  12 U  2.0 P ! .0001
and the mean age at onset was 43.2 years in parents and
17.7 years in children. Therefore, the results presented
in this letter support the hypothesis of anticipation in
familial HL. Nevertheless, as pointed out by Penrose
(1948), false claims of genetic anticipation may be the
result of various selection biases. A more optimal study
design should be based on prospectively selected cases,
as discussed by Horwitz et al. (1996). In addition, in-
fectious agents such as the Epstein-Barr virus (EBV) have
been implicated in the etiology of familial HL. The ob-
served anticipation may also be related to simultaneous
parent-child exposure to viral infection. To unfold this
intriguing relation, further study should focus on cases
who test negative for EBV.
Literature search has its place in terms of retrieval of
data for a metanalysis. However, in 36 publications, only
30 parent-child pairs were eligible for inclusion in this
study, because pairs selected on the basis of certain age
criteria were not suitable for the testing of anticipation.
Another drawback to the use of published data is that
the age at diagnosis of relatives is sometimes not re-
ported, which results in a loss of information. Given the
rarity and complexity of the disease, a large international
collaboration is required, to fully demonstrate the an-
ticipation effect as well as to elucidate the role of genetic
factors in the etiology of familial HL.
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Figure 1 a, SSCA. The arrow indicates the fragment with mo-
bility shift in patient III-1 of family BC10; and the other lanes contain
DNA samples of unrelated BC/OC patients. PCR primers for ampli-
fication of exon 20 were retrieved from the Breast Cancer Information
Core (1997); they are 20F, 5′-cactgtgcctggcctgatac-3′; and 20R, 5′-
atgttaaattcaaagtctcta-3′. Amplification conditions were 35 cycles of
94C for 30 s, 55C for 1 min, and 72C for 30 s; the size of the PCR
product was 296 bp. SSCA was performed as described elsewhere
(Zlotogora et al. 1995). b, Sequence of the 8765delAG mutation in
exon 20 of BRCA2 The PCR fragments with mobility shift in SSCA
were separated on 8% polyacrylamide gel, were excised from the gel,
and were run on 1% low-melt-temperature agarose in tris-acetate/
EDTA buffer. The DNA was cleaned with b-Agarase (NEB) and was
precipitated with isopropanol. The purified PCR fragments were se-
quenced by the dideoxy terminator cycle–sequencing method with
AmpliTaq DNA polymerase, FS (ABI Prism Ready Reaction Kit), and
then were analyzed by use of an automatic DNA sequencer (ABI
PRISM 310). The primers for sequencing were the same as those for
SSCA. c, Restriction analysis (with BsmAI) of the 8765delAGmutation
in family members of the identified carriers. U  uncut; N  normal;
and H  heterozygote. A mismatch was introduced into one of the
primers, and, as a result, the normal allele acquired a BsmAI restriction
site. The PCR primers were 20F and misR (5′-gctgcttccttttcttcg*t-3′),
and the size of the PCR product was 155 bp for the normal allele and
153 bp for the mutant allele. The PCR products were cut by BsmAI
(NEB) and were separated on NuSieve:agarose 3:1, were stained by
ethidium bromide, and were visualized under a UV lamp. In the het-
erozygote, two bands—153 bp and 132 bp—were seen.
disease: its significance and implications. Ann Intern Med
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Hodgkin’s disease: an environmental and genetic disorder.
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The 8765delAG Mutation in BRCA2 Is Common
among Jews of Yemenite Extraction
To the Editor:
The proportion of high-risk families with BRCA2 mu-
tations varies widely among populations. In Iceland, 8%
of unselected breast cancer (BC) patients and 64% of
patients with a definite family history of BC carry a
founder mutation in BRCA2—995del5 (Thorlacius et al.
1997). In the Ashkenazi Jews, the 6174delT mutation
is found in 24% of high-risk families and in 6% of
unselected BC patients (Abeliovich et al. 1997; Levy-
Lahad et al. 1997). Other ancient BRCA2 mutations
have been summarized by Szabo and King (1997).
Whereas some of the BRCA2 mutations were found in
BC-only families, including the majority of families with
male and female BC (Ford et al. 1998), other BRCA2
mutations, such as 6174delT, were found in BC/OC pa-
tients (i.e., those with BC and/or ovarian cancer [OC]).
In this letter, we describe the 8765delAG mutation in
BRCA2, a founder mutation in Jews of Yemenite origin.
During the screening of BC/OC patients for mutations
in the BRCA2 gene, PCR products of two patients (III-
9 in family BC10 and III-6 in family BC149) of Yemenite
extraction had mobility shifts, as determined by single-
strand conformation polymorphism (SSCA) (fig. 1a). Se-
quencing of these fragments revealed a deletion of 2 bp
(AG), one of three AGs starting at position 8761 (fig.
1b). The mutation was analyzed in genomic DNA of the
patients and of their family members, by a BsmAI re-
striction assay using a primer into which a mismatch
was introduced (fig. 1c). Patient II-4 in family BC703
and patient III-2 in family BC703, who were referred to
us because of their ethnic affiliation and positive family
history, were analyzed directly for the mutation. The
pedigrees of the three families are presented in figure 2.
We could not find any relationship among the three fam-
ilies. In families BC10 and BC149, only BC was re-
ported. In family BC703, one of the sisters had BC and
